PL431613A1 - Związek do zastosowania jako lek, inhibitor kinazy PERK oraz jego zastosowanie do zapobiegania i leczenia chorób neurodegeneracyjnych zależnych od stresu retikulum endoplazmatycznego - Google Patents

Związek do zastosowania jako lek, inhibitor kinazy PERK oraz jego zastosowanie do zapobiegania i leczenia chorób neurodegeneracyjnych zależnych od stresu retikulum endoplazmatycznego

Info

Publication number
PL431613A1
PL431613A1 PL431613A PL43161319A PL431613A1 PL 431613 A1 PL431613 A1 PL 431613A1 PL 431613 A PL431613 A PL 431613A PL 43161319 A PL43161319 A PL 43161319A PL 431613 A1 PL431613 A1 PL 431613A1
Authority
PL
Poland
Prior art keywords
treatment
compound
prevention
kinase inhibitor
endoplasmic reticulum
Prior art date
Application number
PL431613A
Other languages
English (en)
Other versions
PL241218B1 (pl
Inventor
Ireneusz Majsterek
Wioletta Rozpędek
Anna Walczak
Jacek Kabziński
Original Assignee
Uniwersytet Medyczny w Łodzi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny w Łodzi filed Critical Uniwersytet Medyczny w Łodzi
Priority to PL431613A priority Critical patent/PL241218B1/pl
Priority to EP20204016.8A priority patent/EP3815682A1/en
Publication of PL431613A1 publication Critical patent/PL431613A1/pl
Publication of PL241218B1 publication Critical patent/PL241218B1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/121Ketones acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Przedmiotem wynalazku jest związek o wzorze ogólnym I, do zastosowania jako lek, związek do zastosowania jako inhibitor kinazy PERK do zapobiegania i leczenia chorób zależnych od stresu retikulum endoplazmatycznego. Korzystnie wspomniane choroby są wybrane z grupy obejmującej jaskrę, chorobę Alzheimera, chorobę Parkinsona.
PL431613A 2019-10-25 2019-10-25 Związek do zastosowania w zapobieganiu i/lub leczeniu chorób neurodegeneracyjnych zależnych od stresu retikulum endoplazmatycznego PL241218B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL431613A PL241218B1 (pl) 2019-10-25 2019-10-25 Związek do zastosowania w zapobieganiu i/lub leczeniu chorób neurodegeneracyjnych zależnych od stresu retikulum endoplazmatycznego
EP20204016.8A EP3815682A1 (en) 2019-10-25 2020-10-27 A perk kinase inhibitor for treating diseases associated with endoplasmic reticulum stress

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL431613A PL241218B1 (pl) 2019-10-25 2019-10-25 Związek do zastosowania w zapobieganiu i/lub leczeniu chorób neurodegeneracyjnych zależnych od stresu retikulum endoplazmatycznego

Publications (2)

Publication Number Publication Date
PL431613A1 true PL431613A1 (pl) 2021-05-04
PL241218B1 PL241218B1 (pl) 2022-08-22

Family

ID=73646059

Family Applications (1)

Application Number Title Priority Date Filing Date
PL431613A PL241218B1 (pl) 2019-10-25 2019-10-25 Związek do zastosowania w zapobieganiu i/lub leczeniu chorób neurodegeneracyjnych zależnych od stresu retikulum endoplazmatycznego

Country Status (2)

Country Link
EP (1) EP3815682A1 (pl)
PL (1) PL241218B1 (pl)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014253A2 (en) 2008-08-01 2010-02-04 University Of Florida Research Foundation, Inc. Ant4 inhibitor compounds and methods of use thereof

Also Published As

Publication number Publication date
PL241218B1 (pl) 2022-08-22
EP3815682A1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
CO2020015176A2 (es) Compuestos novedosos
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
SA520412278B1 (ar) مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات جين أس أوه أس 1
SA521422143B1 (ar) 15-pgdh مثبط
UY38425A (es) Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste
GEP20257731B (en) Substituted aminothiazoles as dgkzeta inhibitors for immune activation
MX2020000261A (es) Nuevos compuestos.
UY38186A (es) Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
MX2020006460A (es) Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
JOP20190193A1 (ar) ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
EP4344743A3 (en) Heterocyclic flavone derivatives, compositions, and methods related thereto
WO2007022380A3 (en) Bis-aryl amide compounds and methods of use
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
WO2018153508A3 (en) INHIBITORS OF SULFOXIMINE GLYCOSIDASE
CL2021003455A1 (es) Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
MY197561A (en) Composition for increasing expression of pgc-1?
MY202753A (en) Griseofulvin compound and pharmaceutical use thereof
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
BR112021011325A2 (pt) Derivados de rapamicina